Autoimmune Disease: Pathophysiology of Loss of Self-Tolerance
Autoimmune disease occurs when the immune system mounts a sustained response against the body’s own tissues. Rather than recognising self-antigens as harmless, immune tolerance breaks down and immune activation is misdirected. This leads to chronic inflammation, progressive tissue injury, and loss of organ function. Autoimmune disease is not a single mechanism but a spectrum of immune failures involving both innate and adaptive responses. Understanding how self-tolerance is lost explains why these conditions are chronic, relapsing, and often systemic.
What You Need to Know
Autoimmune disease develops when the immune system loses the ability to distinguish self from non-self. Under normal conditions, immune tolerance mechanisms eliminate or inactivate autoreactive lymphocytes during development and maintain control in the periphery. In autoimmune disease, these safeguards fail, allowing autoreactive T cells and B cells to survive and become activated. Once triggered, immune responses are directed against the body’s own tissues and tend to persist rather than resolve, establishing chronic inflammation.
Autoimmune injury can occur through different immune pathways. Some conditions are dominated by antibody-mediated mechanisms, where autoantibodies bind to self-antigens and disrupt normal function or mark tissue for immune attack. Other diseases are driven primarily by T-cell–mediated inflammation, where immune cells infiltrate tissues and release cytokines that damage structure and function. In many autoimmune diseases, these mechanisms coexist and interact, amplifying tissue injury and shaping disease behaviour.
Several shared processes explain why autoimmune diseases are chronic and progressive rather than self-limited:
failure of immune tolerance allowing autoreactive lymphocytes to persist
sustained immune activation driven by self-antigen exposure rather than infection
cumulative tissue damage from repeated inflammatory episodes
Autoimmune disease activity commonly fluctuates over time, with periods of relative remission interrupted by flares of immune activation. These fluctuations may be influenced by internal immune shifts, hormonal changes, infections, or environmental factors. Importantly, even when symptoms improve, underlying immune activity may continue at a lower level. Repeated inflammatory episodes lead to progressive tissue injury, and over time this chronic inflammation results in irreversible structural and functional changes. Autoimmune disease is therefore defined not only by active inflammation, but by the long-term consequences of immune dysregulation and cumulative damage.
Beyond the Basics
Failure of central and peripheral tolerance
Immune tolerance is maintained through complementary central and peripheral mechanisms. Central tolerance acts during immune cell development, eliminating strongly autoreactive lymphocytes before they enter circulation. Peripheral tolerance provides additional control by suppressing or inactivating autoreactive cells that escape deletion, using regulatory cells and inhibitory signalling pathways. Failure at either level increases the likelihood that autoreactive lymphocytes remain active within the immune system.
When these safeguards fail, autoreactive cells are no longer adequately restrained. Once activated, they can persist long term because the antigen driving the response is self and therefore continuously present. This ongoing exposure allows immune activation to become chronic rather than self-limited, establishing the foundation for autoimmune disease.
Genetic susceptibility and immune thresholds
Autoimmune disease arises from altered immune thresholds rather than global immune malfunction. Genetic variations influence how readily immune cells activate, how strongly they respond to stimulation, and how effectively regulatory mechanisms suppress inappropriate responses. In genetically susceptible individuals, immune activation occurs more easily and is less effectively downregulated. As a result, stimuli that are normally tolerated, such as minor infections, tissue stress, or hormonal changes, can trigger exaggerated or misdirected immune responses. This helps explain why autoimmune diseases cluster within families and why individuals with one autoimmune condition are at increased risk of developing others.
Autoantibody production and immune complex formation
In antibody-mediated autoimmune disease, autoreactive B cells produce antibodies directed against self-antigens. These autoantibodies may interfere directly with normal tissue function or bind to antigens to form immune complexes. Immune complexes activate complement and attract inflammatory cells, amplifying tissue injury. When immune complexes deposit within tissues or blood vessels, they provoke local inflammation and vascular damage. This process disrupts normal organ function and can produce widespread effects when circulating immune complexes affect multiple sites simultaneously.
Cell-mediated tissue injury
Some autoimmune diseases are driven predominantly by T-cell–mediated mechanisms rather than antibodies. Activated T cells infiltrate target tissues and release cytokines that promote inflammation and recruit additional immune cells. Cytotoxic T cells may directly damage host cells through contact-dependent mechanisms. In these conditions, tissue injury progresses even when circulating autoantibodies are minimal or absent. Damage is sustained by ongoing cellular infiltration and inflammatory signalling within the affected organ, leading to progressive loss of structure and function.
Chronic inflammation and progressive damage
Autoimmune inflammation is self-perpetuating because tissue injury releases additional self-antigens into the immune environment. These newly exposed antigens further stimulate autoreactive lymphocytes, sustaining immune activation over time. With repeated cycles of injury and repair, inflammation becomes chronic rather than episodic.
Long-standing inflammation promotes fibrosis, scarring, and irreversible tissue damage. Functional reserve is gradually lost, meaning clinical impact increases even if inflammatory activity fluctuates. This progression explains why early and sustained disease control is critical, as preventing repeated immune-mediated injury limits cumulative structural damage and preserves long-term organ function.
Clinical Connections
Autoimmune disease frequently presents with non-specific features such as fatigue, pain, cognitive slowing, and fluctuating functional capacity, which reflect systemic immune activation rather than isolated organ pathology. Organ-specific manifestations depend on the tissues targeted by immune responses, but overlap between conditions is common, contributing to diagnostic delay and fragmented assessment. Because immune activation may be intermittent or evolve over time, symptoms often appear inconsistent, with periods of relative stability followed by deterioration without an obvious external trigger.
Several recurring clinical patterns arise from immune dysregulation rather than single-organ failure:
fluctuating symptoms driven by changes in immune activation rather than structural progression alone
involvement of multiple organ systems over time as immune targets expand or shift
increased cardiovascular and metabolic risk associated with chronic inflammation, even when disease appears clinically controlled
Assessment and management therefore require longitudinal, system-based evaluation rather than reliance on isolated findings. Disease activity may not be captured by single laboratory values or symptom reports, and treatment effects must be balanced against risks related to immune suppression, infection, and metabolic complications. Ongoing monitoring focuses on detecting flares early, identifying evolving organ involvement, and recognising treatment-related harm alongside disease activity.
Long-term care is directed at modifying immune behaviour rather than eliminating immune activity entirely. The goal is to reduce inappropriate immune activation, limit cumulative tissue injury, and preserve functional reserve across organ systems. Outcomes are shaped by how effectively immune dysregulation is contained over time, rather than by short-term symptom suppression or episodic intervention alone.
Concept Check
What is meant by loss of self-tolerance?
How do antibody-mediated and cell-mediated autoimmune diseases differ?
Why do autoimmune diseases fluctuate over time?
How does chronic inflammation lead to irreversible tissue damage?
Why do autoimmune diseases often cluster within individuals?